The FDA initially granted accelerated approval for palbociclib in February 2015, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor (ER)-positive, HER2− advanced breast cancer as initial endocrine-based therapy for metastatic disease [25]. The gene discussed is ESR1; the disease is breast carcinoma.